Galanin is a biologically active 29 amino acid peptide, widely distributed in the central and peripheral nervous system, and most abundantly in the hypothalamus where it may serve in the regulation of anterior pituitary hormones. We herein report that mice carrying the rat preprogalanin cDNA specifically targeted to the somatomammotroph cell lineage, under the control of the rat GH promoter, over-express and over-secrete galanin. Galanin peptide is localised within the GH and prolactin secretory granules. GH and prolactin release is increased as well, predominantly in males, while older transgenic animals develop pituitary hyperplasia and adenoma. In both male and female transgenic mice there is a significant increase in serum galanin (P,0·00003 and P,0·001 respectively) and prolactin (P,0·002 and P,0·05 respectively) levels, while only in male transgenic mice is there a significant increase in the serum levels of GH. Furthermore, in male transgenic mice serum prolactin levels are significantly correlated with the serum galanin levels (P,0·03). We conclude that galanin plays a key role in the process of pituitary hyperplasia, acting as a growth factor to promote pituitary cell proliferation, and participates in pituitary adenoma formation not necessarily dependent on oestrogens. Targeted over-expression and over-secretion of galanin in the somatomammotroph cell lineage stimulates predominantly hyperprolactinaemia in an oestrogenindependent manner.
Introduction
Galanin is a biologically active 29 amino acid peptide widely distributed in the central and peripheral nervous system (Vrontakis et al. 1991 , Merchenthaler et al. 1993 and, most abundantly, in the hypothalamus, where it may serve in the regulation of anterior pituitary hormones (Ottlecz et al. 1988 , Bartfai et al. 1993 . In vitro studies have shown that galanin may regulate hormone secretion directly at the level of the pituitary gland , Wynick et al. 1993a , Cai et al. 1998 . In the rat, central administration of galanin results in increased plasma levels of growth hormone (GH) and prolactin (PRL) in a dose-dependent manner (Ottlecz et al. 1986 , Koshiyama et al. 1987 , Murakami et al. 1989 . In humans, intravenous administration of galanin increases plasma GH levels (Bauer et al. 1986 ) and enhances the GH response to exogenous growth hormone releasing hormone (GHRH) (Davis et al. 1987 , Carey et al. 1993 , Chan et al. 1996 . Immunohistochemical studies indicate that in normal female rats, galanin is detected mainly in lactotrophs, and to a lesser extent in somatotrophs and thyrotrophs (Steel et al. 1989 , Hyde et al. 1991 . In the male rat, on the other hand, galanin expression has been confirmed in somatotrophs and, in some studies, thyrotrophs (Steel et al. 1989 , Moore et al. 1999 . In Dwarf mice, where there is failure of acidophilic proliferation, galanin is also lacking (Hyde et al. 1993) . We and others have previously demonstrated that galanin is dramatically up-regulated by oestrogens in the anterior pituitary (Kaplan et al. 1988 , Vrontakis et al. 1989 , primarily within the lactotrophs of both sexes (Steel et al. 1989 , Hyde et al. 1991 , suggesting that the peptide can be present in the same cell type in males and females, depending on the status of oestrogen levels. During pituitary hyperplasia, induced by oestrogen, a correlation exists between the development of pituitary hyperplasia and the increase in galanin mRNA (messenger ribonucleic acid) and peptide concentration (Vrontakis et al. 1987 , Kaplan et al. 1988 , Hsu et al. 1990 . However, it is difficult to distinguish whether galanin's mitogenic action is dependent on oestrogen. To further establish the functional role(s) of endogenous galanin in the anterior pituitary, we have created transgenic mice that overexpress and over-secrete galanin.
Materials and Methods

Generation of galanin transgenic mice
The transgene was constructed using a 320 bp KpnI/BamHI fragment of the rat GH promoter (generously provided by Dr Cattini, University of Manitoba, Canada), fused to the rat preprogalanin cDNA (complementary DNA) clone (full length) including its poly A tail (provided by Dr Vrontakis), followed by the poly A tail of the rat GH gene (PvuII 237 bp fragment). The rat GH promoter 320 bp fragment with the BamHI modified site at position (+7) to XhoI was used. This fragment contains the pituitary specific elements to specifically target to somatotrophs (Lira et al. 1988) . The 320 bp Kpn/XhoI fragment was isolated, the XhoI site was filled in and the Kpn/blunt fragment was inserted in the Kpn/ Sma site of the PUC 119 vector. The poly A tail of the rat GH gene was obtained by digesting the PvuII sites of the 5·8 kb GH gene and isolating the 273 bp fragment. This PvuII/PvuII fragment was inserted in the Xba/blunt site of the Kpn/SmaI(GH)/PUC 119 construct and the right orientation was chosen by checking the size of the PstI fragments of the transformants on agarose gel. Finally, the EcoRI fragment of the rat galanin cDNA (Vrontakis et al. 1987) was blunted by filling in with klenow and inserted in the blunted BamHI site of the GH/PUC 119 construct. The transgene was purified by electroelution from 1% agarose gel, followed by CsC1 purification. DNA sequencing (Sequenase, version 2·0, U.S Biochemical Corp., Cleveland, OH, USA) through the junction segments verified the fidelity of the hybrid construct. Pronuclear injections of the transgene into mouse embryos were carried out by DNX Facilities (Washington DC, USA). Identification of transgenic mice was carried out by Southern blot analysis of genomic DNA obtained from 0·5 cm sections of tails from 3-week-old mice by digestion with proteinase K. Genomic DNA was digested with the restriction enzyme RSA1, blotted onto 1·5% agarose gel and transferred to a nylon membrane. Southern hybridisation was performed using the rat galanin cDNA probe labelled with [ 32 P] ATP, that gave rise to a 600 bp hybrid fragment only in the transgenic animals.
Animals
All mice were housed under controlled temperature and lighting conditions and water and laboratory chow were available ad libitum. Founders were a C578BL6 SJL F 2 background. For the generation of lines they were crossed with Swiss CD for at least four generations. The Animal Protocol Review Board of the University of Manitoba has approved the research (R96-064). In our experiments we have compared transgenic mice with wild-type controls (non-transgenic) of similar genetic background, gender and age. For each experiment at least seven animals per group were used and each experiment was reproducible at least three times.
RNA extraction and Northern blot analysis
Mice were killed by decapitation, and the dissected tissues were rapidly frozen in liquid nitrogen. Total RNA was prepared from each pituitary individually, using the guanidine isothiocyanate method, and hybridisation was performed using the rat galanin cDNA probe as previously described (Vrontakis et al. 1992) .
RIA
Blood was collected by cardiac puncture under ether anaesthesia. Galanin serum levels were measured by RIA, as previously described (Vrontakis et al. 1992) . Mouse (m) GH serum levels were determined by RIA (mGH RIA kit), using materials supplied by Dr A F Parlow (Harbor-University of California-Los Angeles Medical Center) and according to their protocol. The sensitivity of the GH assay was 0·78 ng/ml. For PRL we used mPRL reagents for RIA generously supplied by Dr F Talamantes, Sinsheimer Laboratories, University of California (Lopez & Talamantes 1983) .
Morphological analysis of pituitary glands
Mice were killed by decapitation and the pituitaries were removed. Each pituitary was cut into halves, one half for light microscopy, the other half for electron microscopy (EM). Tissues were fixed in 10% neutral buffered formalin and embedded in paraffin. Sections (4-5 mm thick) were stained with haematoxylin and eosin and with Gordon Sweet silver staining to demonstrate the reticulin fibre network.
Immunocytochemistry was performed with the avidinbiotin-peroxidase complex technique (Hsu et al. 1981) . The duration of incubation to primary antisera was 24 h at 4 C. The primary antisera were directed against the following antigens: rat Galanin (Peninsula Laboratory (Belmont, CA, USA)), dilution 1:1000; GH, luteinising hormone (LH) and thyrotrophin (TSH) (all donated from the National Hormone and Pituitary Program NIDDK, NICHHD, Bethesda, MD, USA), dilution 1:2500; and mPRL (from Dr Talamantes, Sinsheimer Laboratories, University of California (Lopez & Talamantes 1981) ), dilution 1:2000.
For EM study, pituitary glands were cut into small pieces and fixed in 4% paraformaldehyde/0·125% glutaraldehyde in 0·1 M phosphate buffer (pH 7·4) for 4 h, post fixed with 1% osmium for 1 h, rinsed with water and embedded in Araldite (White Electron Microscopy Sciences, Fort Washington, PA, USA). Thin sections were collected on nickel grids, treated with normal goat serum for 15 min, incubated with primary antibody for 3 h, rinsed with universal blocking agent and incubated for 1 h in goat antirabbit immunoglobulin G (IgG) conjugated with 5 nm gold spheres (British Biocell, Cedarlane Laboratories, ON, USA). Sections were rinsed, placed in 2·5% buffered glutaraldehyde for 30 min and rinsed again. Sections were then treated with normal goat serum for 15 min, and incubated with the second primary antibody for double immunogold staining for 3 h, rinsed and incubated for 1 h in either goat antimouse IgG (rat absorbed) conjugated with 10 nm gold spheres (British Biocell), with the use of PRL primary antibody (BioGenex Laboratories, San Ramon, CA, USA), or goat antimonkey immunoglobulin conjugated with 10 nm gold spheres (E-Y Laboratories, Inc, San Mateo, CA, USA), with the use of GH primary antibody (donated from the National Hormone and Pituitary Program, NIDDK). Finally, sections were rinsed, fixed in 2·5% buffered glutaraldehyde, stained with uranyl acetate and lead citrate, and viewed and photographed in a Philips EM 201 electron microscope.
Statistical analysis
All data are expressed as the means S.E.M Statistical analysis for all comparisons was performed using the Student's t-test. Regression analysis (Pearson) was performed to analyse the effect of galanin serum levels on GH and PRL with 95% confidence.
Results
Detection of the galanin transgene
The presence of the transgene in mice was confirmed by restriction analysis of genomic DNA. Tail DNA from the pups was digested with RSA1 restriction enzyme, subjected to electrophoresis, capillary blotted onto nylon membrane and probed with a radiolabelled full-length rat galanin cDNA fragment. This probe hybridises to a 900-bp fragment from the endogenous galanin gene and a 600-bp fragment of the GH-galanin fusion gene construct unique to the transgenic mice. The endogenous gene served as a copy number control (Fig. 1A) . Analysis of 50 mice identified four transgenic animals, all females, which contained a high copy number of the galanin transgene. Out of the four female founders, one was infertile. Some of the female offspring were also infertile.
Over-expression of galanin
Using Northern blot analysis we were able to demonstrate a dramatic increase in galanin gene expression in the anterior pituitary of both male and female transgenic animals. As shown in Fig. 1B , there is a strong induction of the galanin transcript in the pituitaries of transgenic mice. This induction was detectable at all ages of transgenic mice examined (from 3 to 20 months). Northern blot analysis of RNA from other tissues, including ovary, testis, spleen, liver and fat did not show any difference between transgenic and non-transgenic animals (data not shown).
Galanin peptide was also increased in the anterior pituitary of the galanin transgenic mice, as demonstrated by immunohistochemistry of serial pituitary sections. Formalin fixed, paraffin embedded pituitaries were examined by histology and immunohistochemistry. Figure 2 shows pituitaries from transgenic and nontransgenic animals. The pituitaries of both male and female transgenic mice contained several cells for galanin (Fig. 2C ) that were much greater in number and density compared with non-transgenic control mice (Fig. 2D ). Regarding the cell type, both GH and PRL cells exhibited galanin staining. GH and PRL immunostaining cells were also increased both in number and density in transgenic pituitaries compared with non-transgenic control pituitaries (Fig. 3) . Hyperplastic pituitary cells were stained for galanin, GH and PRL but not for TSH or LH (data not shown).
Increased galanin, growth hormone and prolactin serum levels in galanin transgenic mice
Serum galanin, prolactin and growth hormone levels were measured by RIA. Quantitative analysis of serum Figure 1 (A) Screening of pups for integration of the transgene, using Southern blot analysis. Tail DNA from the pups was digested with RSA1 restriction enzyme, subjected to electrophoresis, capillary blotted onto nylon membrane and probed with a radiolabelled full-length rat galanin cDNA fragment. This probe hybridises to a 900-bp fragment from the endogenous galanin gene and a 600-bp fragment of the GH-galanin fusion gene construct unique to the transgenic animals (arrow). The endogenous gene served as a copy number control. NT=non-transgenic (control). (B) Northern blot analysis of mouse pituitary mRNA. Total RNA was obtained from individual pituitaries of both male (m) and female (f) transgenic (+) and control (-) animals. The RNA was purified, subjected to electrophoresis, capillary blotted onto nylon membrane, and hybridised to the full-length rat galanin cDNA. The variability in RNA loading and transfer is shown in the lower part of the Figure using a 28S radiolabel probe to reprobe the blot. levels demonstrated that galanin levels were significantly elevated in both male and female transgenic animals (12 months old) compared with non-transgenic control mice (male: from 896 109 pg/ml to 7800 737 pg/ml, P,0·00003; female: from 680 112 pg/ml to 3500 723 pg/ml, P,0·001) (Fig. 4) . There was a sex difference in this elevation with a much higher response in males than in females (7800 pg/ml vs 3500 pg/ml, P,0·02). Thus, there was a main effect of gender and genotype on galanin serum levels. Regarding PRL and GH levels (Figs 5 and 6) both were elevated in transgenic animals but while in male transgenic mice the increase in both GH and PRL serum levels was significant (P,0·05 and P,0·002 respectively), in females only the increase in PRL was significant (P,0·05). The increase in both GH and PRL levels was much greater in males compared with females. In male transgenic mice prolactin serum levels were increased almost 9-fold compared with a 2-fold increase in female transgenic animals, while GH was increased 3·3-fold in males compared with 1·3-fold in females. Furthermore, in male transgenic mice PRL serum levels were significantly correlated with galanin serum levels (P,0·03).
Immunogold labelling
Using the double immunogold labelling technique on ultra-thin sections and electron microscopy, we were able to visualise the coexistence of galanin within the GH and prolactin secretory granules. As shown in Fig. 7 , both GH and PRL secretory granules of male transgenic mice contained galanin. While most of the GH and PRL granules contained galanin, there were some granules that contained only galanin.
Growth effect of galanin
Mice of 8 months of age and older developed pituitary adenomas, as demonstrated by the total breakdown of the reticulin fibre network (Fig. 2 E, F) . At 12 months of age the pituitary of transgenic animals was visibly larger than the controls (Fig. 8) .
Discussion
Our present results have proven that pituitary galanin may act as a growth factor by causing pituitary cell hyperplasia and later on tumour formation. This activity is independent of oestrogen status, since both male and 
Figure 4
Galanin serum levels in male and female, transgenic and non-transgenic animals. The values are the means S.E.M. Both male and female transgenic animals have significantly elevated levels (male P,0·00003, female P,0·001). This increase is much higher in males than in females, resulting in a statistically significant difference in their galanin serum levels (P,0·02).
female animals developed pituitary hyperplasia (as evident from the morphological studies, both microscopic and macroscopic, of the mouse pituitaries). Hyperplastic pituitary cells were stained for galanin, GH and PRL but not for TSH or LH, indicating that only the somatomammotroph cell lineage was affected. Since we used the rGH promoter, the transgene was initially targeted to the somatotroph cells. As has previously been shown (Lira et al. 1988) , the use of the rat 320 bp promoter in transgenic constructs is enough to target the expression of the transgene specifically to the somatotrophs. There is enough evidence to suggest that the majority of PRL-expressing cells appear to be derived from the GH-producing precursor (Andersen & Rosenfeld 1994) . Complete ablation of somatotrophs by expression of GHdiphtheria toxin and GH-thymidine kinase fusion genes inserted into the germ line of transgenic mice also resulted in the elimination of most of the lactotrophs (Behringer et al. 1988 , Borelli et al. 1989 ). These observations support the lineal relationship between somatotrophs and lactotrophs. This can explain the over-expression of the galanin gene in both somatotrophs and lactotrophs of our transgenic mice. Thus, over-expression of galanin in the anterior pituitary using the rat GH promoter has influenced both the lineage of somatotrophs and the differentiation of lactotrophs from somatotrophs. Creation of galanin transgenic mice using the rat PRL promoter has resulted similarly in the formation of pituitary hyperplasia and later on tumour formation. However, in these animals galanin was over-expressed only in the lactotrophs and hyperplasia was limited to the lactotrophs of female mice, indicating that hyperplasia is limited to the cell type in which galanin has been over-expressed, possibly through an autocrine mechanism. It could also imply that the proliferative effect of galanin in lactotrophs is a post mitotic event in that model and is oestrogen dependent.
Mice aged 8 months and older developed pituitary adenomas. This was demonstrated by the total breakdown of the reticulin fibre network. These data are in agreement with previous observations, suggesting that galanin mRNA levels correlate with tumour formation. In both oestrogen-induced pituitary tumours and in GHRH transgenic mice pituitary tumours, galanin mRNA levels and protein were closely correlated with the development of these tumours (Vrontakis et al. 1987 , Moore et al. 1994 ). Our present data give direct causal evidence for the growth promoting effects of galanin in vivo in both somatotrophs and lactotrophs. In previous studies, it has been shown that using the rat GH promoter for overexpression of other gene products, such as herpes thymidine kinase, does not lead to any noticeable change in cell phenotype or function (Borelli et al. 1989) . Therefore, we conclude that the hyperplasia and adenoma formation are specific consequences of the over-expression of galanin.
One puzzling question is the late onset of adenoma, despite the early detection of galanin's over-expression and over-secretion. We propose that some additional growth factors might have been removed or replaced in older animals or that the continuous supply of galanin may disrupt an intracellular signal transduction system. Interestingly, it has been reported that the rat pituitary galanin gene expression profile is associated with aging and spontaneous tumours (Goidin et al. 2000) . Previous animal Figure 5 PRL serum levels in male and female, transgenic and non-transgenic animals. The values are the means S.E.M. Both male and female transgenic animals have significantly elevated levels (male P,0·002, female P,0·05). This increase is much higher in males compared with females. Transgenic male PRL levels are significantly correlated to the transgenic male galanin levels (P,0·03).
Figure 6 GH serum levels in male and female, transgenic and non-transgenic animals. The values are the means S.E.M. GH levels are higher in transgenic animals compared with nontransgenic animals. However, this increase is significant only in the male transgenic mice (P,0·05). models of pituitary tumorigenesis (Asa et al. 1992 , Borelli et al. 1992 , Lloyd et al. 1992 , McAndrew et al. 1995 had also shown the development of multifocal pituitary adenoma in older animals, after prolonged hyperplasia. In the human, the majority of pituitary adenomas develop from transformed cells that are dependent on hormonal and/or growth factor stimulation for tumour progression (Asa & Ezzat 1998) . Thus, both in humans and these animal models it is evident that hyperplasia precedes the development of pituitary adenoma. The observation that naturally occurring pituitary adenomas are monoclonal in nature suggests that a mutational event occurs, allowing the proliferation of a clonal cell line to form the adenoma. In both male and female transgenic animals galanin was over-secreted. This over-secretion was more pronounced in transgenic males (9-fold increase compared with nontransgenic males) than females (5·3-fold increase compared with non-transgenic females). Both in transgenic and non-transgenic animals galanin serum levels were sexually dimorphic, with higher levels in males compared with females. In the transgenic animals the difference in the galanin serum levels between males and females was statistically significant (male=7800 737 pg/ml, female= 3500 723 pg/ml, P,0·02). Sexual dimorphism for galanin has been reported previously. Galanin immunoreactivity has been reported to be higher in the rat male spinal cord (Newton 1999 , Phelan & Newton 2000 , in discreet regions of the brain in mice and rats (Rugarn et al. 1999 , Rajendren et al. 2000 and in GHRH neurons in mice (Delemarre-van de Waal et al. 1994 ). In our transgenic animals the galanin transgene was expressed in both males and females, indicating that the GH promoter is activated in both males and females. The fact that galanin serum levels were significantly higher in males compared with females might imply that the 320 bp fragment of the GH promoter is more active in males than females, possibly due to additional transcription factors (testosterone) in the male pituitary. The fact that GH secretion in the rat (Eden 1979 , Jansson et al. 1985 is sexually dimorphic supports this possibility. Using the rat PRL promoter, Hyde's group was not able to demonstrate any measurable increase in galanin serum levels. Since the GH promoter is activated earlier (embryonic day 15) than the PRL promoter, the earlier and stronger expression of galanin might account for this difference. Thus, this model of galanin transgenic mice is unique compared with other galanin transgenic models (Crawley et al. 2002) in that galanin is over-secreted in the circulation. This feature makes these mice an excellent model in which to study the functional significance of galanin.
Double immunogold histochemistry of anterior pituitary thin sections at the electron microscopy level revealed colocalisation of galanin within the same secretory granules of GH and PRL cells. In transgenic animals almost all of the GH and PRL secretory granules contained galanin immunogold particles, although the ratio of galanin to GH or to PRL immunogold particles was different from cell to cell, and within the same cell from granule to granule. Very few secretory granules were stained with galanin immunogold particles alone. The colocalisation of galanin within the secretory granules of certain lactotrophs and somatotrophs has previously been reported (Hyde et al. 1991) . The interesting finding in our model is that almost all the lactotroph and somatotroph cells contained galanin, further supporting the notion of transmission of the galanin transgene in the progenital somatomammotroph stem cell of our transgenic model. Thus galanin is not only over-produced in the somatomammotroph population of cells in our transgenic model, but is also over-secreted from them. This finding makes this particular galanin transgenic model very attractive for further exploration of galanin's functions.
Galanin transgenic mice exhibited hyperprolactinaemia that was much more pronounced in males compared with females (9-fold increase in males, P,0·002, and 2·13-fold increase in females, P,0·05) resulting in higher PRL levels in male transgenic compared with female transgenic mice. Regression analysis showed a significant correlation of PRL and galanin levels in the serum of the male transgenic mice (P,0·03), indicating the dependence of PRL secretion from galanin. The predominant effect of galanin on PRL is also supported by the observations of Dr Wynick's group on the galanin knock-out mice phenotype, where PRL serum levels were also reduced (Wynick et al. 1998) . GH serum levels were also significantly elevated in our male transgenic (3·2-fold increase, P,0·05), but not in the female transgenic mice. The prevalence of hyperprolactinaemia in our male transgenic mice could be due to the higher serum levels of galanin in males and therefore an increase in the number of somatomammotrophs and the rate of differentiation of lactotrophs from progenitor somatotrophs. Furthermore, higher galanin serum levels may up-regulate galanin receptor expression in the anterior pituitary resulting in a gender difference in the responsiveness to galanin. Thus, given the opportunity under the circumstances of our transgenic model, galanin appears to regulate lactotroph hyperplasia and hyperprolactinaemia in a genderdependent and oestrogen-independent manner. Three galanin receptors have been characterised to date, GalR1, GalR2 and GalR3 (Fathi et al. 1997 , Wang et al. 1997 , Iismaa et al. 1998 , Branchek et al. 2000 . GalR1 is expressed in the central and peripheral nervous system, including the hypothalamus, while GalR2 is more abundant in the pituitary (O'Donnell et al. 1999 , Waters & Krause 2000 . Galanin seems to mediate the lactotroph proliferation induced by oestrogens, and to stimulate prolactin secretion via the pituitary specific galanin receptor of Dr Wynick (Wynick et al. 1993b ) that is possibly similar to the GalR2 receptor. However, the fact that Dr Wynick's receptor was defined by binding only assays, casts some doubts about this possibility. Sequence analysis of Dr Wynick's receptor would confirm the similarity. On the other hand, hypothalamic GalR1 receptors could mediate the GH response via an increase in the release of GHRH or a decrease in the release of somatostatin. Furthermore, the effect of galanin on GH release may be mediated via a direct effect on the somatotrophs, perhaps by sensitising the cell to GHRH. In rat embryos galanin receptors are expressed as early as embryonic day 15 (dayE15) (Xu et al. 1996) . Developmentally, the rat GH promoter is active much earlier (dayE15) than the rat PRL promoter (postnatal day 1). Thus the targeted over-expression of galanin should occur earlier in embryonic life in our transgenic model, compared with postnatal expression of galanin in the transgenic model using the rat PRL promoter.
In summary, targeted over-expression and oversecretion of galanin in the somatomammotroph cell lineage stimulates predominantly hyperprolactinaemia in an oestrogen-independent manner. This is the first demonstration of galanin's function in an oestrogen-independent manner. Galanin seems to play a key role in the process of pituitary hyperplasia, acting as a growth factor to promote pituitary cell proliferation and participating in pituitary adenoma formation.
